{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0075733\nAge: 51\nGender: Male\nSample ID: P-0075733-T02-IM7\nGene Panel: IMPACT505\nCancer Type: Pancreatic Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 70.0%\n=============\nDNA Variants:\nCCNE1 c.1106T>G (p.L369W) - in 14.00% of 469 reads\nCDKN2A c.172_176inv (p.R58_V59delinsTR) - in 24.00% of 402 reads\nKDM6A c.2832+2T>G (p.X944_splice) - in 32.00% of 188 reads\nKRAS c.35G>A (p.G12D) - in 21.00% of 447 reads\nLATS1 c.3040_3042delinsCAT (p.D1014H) - in 22.00% of 418 reads\nRUNX1 c.706_718del (p.M236Hfs*14) - in 18.00% of 555 reads\nTP53 c.814G>A (p.V272M) - in 27.00% of 458 reads\nWHSC1 c.2863G>C (p.G955R) - in 25.00% of 472 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Pancreatic Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Gemcitabine plus nab-paclitaxel\",\n    \"Prior Treatment or Resistance Status\": \"No prior treatment specified\",\n    \"Genomic Features\": {\n      \"KRAS G12D mutation\": \"KRAS mutations are common in pancreatic cancer; targeted therapies are under investigation but currently not standard.\",\n      \"TP53 mutation\": \"Common tumor suppressor mutation; no targeted therapy available.\",\n      \"CDKN2A deletion\": \"Loss of CDKN2A suggests potential benefit from CDK4/6 inhibitors in some contexts, but not standard for pancreatic cancer.\",\n      \"KDM6A mutation\": \"Epigenetic modifier; no approved targeted therapy.\"\n    },\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs\"\n  }\n}"
}